KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)Dividends Paid - Common (QoQ)Dividends Paid - Common Growth (1y)Dividends Paid - Common Growth (3y)Dividends Paid - Common Growth (5y)Dividends payables (QoQ)Dividends payables Growth (1y)Dividends payables Growth (3y)Dividends payables Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)FCF Payout Ratio (QoQ)FCF Payout Ratio Growth (1y)FCF Payout Ratio Growth (3y)FCF Payout Ratio Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Sales Growth (1y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)Tax Rate Growth (1y)Tax Rate Growth (3y)Tax Rate Growth (5y)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)
Income Statement
Others
Ratios

Merck (MRK) Free Cash Flow Growth (1y) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (1y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - 36.22%
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 1,827.56%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -56.64%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 154.57%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 149.74%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 50.71%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 46.82%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 23.04%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -55.31%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 149.74%
Dec 31, 2025 -27.42%
Sep 30, 2025 -19.66%
Jun 30, 2025 -47.81%
Mar 31, 2025 -47.42%
Dec 31, 2024 438.22%
Sep 30, 2024 24.84%
Jun 30, 2024 76.93%
Mar 31, 2024 571.39%
Dec 31, 2023 -122.65%
Sep 30, 2023 52.26%
Jun 30, 2023 -13.68%
Mar 31, 2023 -91.21%
Dec 31, 2022 -15.59%
Sep 30, 2022 23.48%
Jun 30, 2022 216.04%
Mar 31, 2022 2,290.51%
Dec 31, 2021 96.41%
Sep 30, 2021 183.20%
Jun 30, 2021 -25.68%
Mar 31, 2021 156.63%
Dec 31, 2020 348.93%
Sep 30, 2020 -60.82%
Jun 30, 2020 -41.31%
Mar 31, 2020 -137.65%
Dec 31, 2019 -129.85%
Sep 30, 2019 52.66%
Jun 30, 2019 -17.76%
Mar 31, 2019 5.11%
Dec 31, 2018 -19.40%
Sep 30, 2018 232.75%
Jun 30, 2018 -4.27%
Mar 31, 2018 1,430.19%
Dec 31, 2017 7.24%
Sep 30, 2017 -162.92%
Jun 30, 2017 138.69%
Mar 31, 2017 -102.80%
Dec 31, 2016 -17.91%
Sep 30, 2016 -14.46%
Jun 30, 2016 -49.51%
Mar 31, 2016 -8.99%
Dec 31, 2015 346.10%
Sep 30, 2015 -25.65%
Jun 30, 2015 20.52%
Mar 31, 2015 -3.48%
Dec 31, 2014 -158.72%
Sep 30, 2014 12.08%
Jun 30, 2014 4.57%
Mar 31, 2014 8.34%
Dec 31, 2013 151.89%
Sep 30, 2013 31.89%
Jun 30, 2013 -22.66%
Mar 31, 2013 9.16%
Dec 31, 2012 -60.80%
Sep 30, 2012 -34.27%
Jun 30, 2012 0.08%
Mar 31, 2012 30.49%
Dec 31, 2011 -8.65%
Sep 30, 2011 83.94%
Jun 30, 2011 -16.77%
Mar 31, 2011 36.56%
Dec 31, 2010 70.85%
Sep 30, 2010 466.27%
Jun 30, 2010 678.53%
Mar 31, 2010 114.24%